BiTE: Teaching antibodies to engage T-cells for cancer therapy.

摘要: Bispecific T-cell-engager (BiTE) antibodies are designed to transiently engage cytotoxic T-cells for lysis of selected target cells. Although this therapeutic concept had been proposed more than two decades ago, BiTE, and also trispecific, did not achieve clinical proof-of-concept until the past 2 years. Their activity corroborates findings that ex vivo expanded, autologous derived from tumor tissue, or transfected with specific T-cell receptors, have shown potential in treatment solid tumors. While these personalized approaches prove alone can considerable activity, even late-stage cancer, they cumbersome perform on a broad basis. This is different T-lymphocyte antigen 4 (CTLA-4) antibodies, which facilitate generation tumor-specific clones, bi- tri-specific directly large proportion patients' cancer cell lysis. The global engagement human therapy by T-cell-engaging has yet be fully investigated.